Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Receivables - Net (2022 - 2024)

Historic Receivables - Net for Avidity Biosciences (RNA) over the last 3 years, with Q1 2024 value amounting to $1.6 million.

  • Avidity Biosciences' Receivables - Net changed N/A to $1.6 million in Q1 2024 from the same period last year, while for Mar 2024 it was $1.6 million, marking a year-over-year change of. This contributed to the annual value of $1.1 million for FY2023, which is 5325.72% down from last year.
  • Latest data reveals that Avidity Biosciences reported Receivables - Net of $1.6 million as of Q1 2024.
  • In the past 5 years, Avidity Biosciences' Receivables - Net registered a high of $2.4 million during Q4 2022, and its lowest value of $1.1 million during Q4 2023.
  • Its 3-year average for Receivables - Net is $1.6 million, with a median of $1.4 million in 2023.
  • Data for Avidity Biosciences' Receivables - Net shows a peak YoY increase of 5325.72% (in 2023) and a maximum YoY decrease of 5325.72% (in 2023) over the last 5 years.
  • Quarter analysis of 3 years shows Avidity Biosciences' Receivables - Net stood at $2.4 million in 2022, then plummeted by 53.26% to $1.1 million in 2023, then surged by 42.53% to $1.6 million in 2024.
  • Its last three reported values are $1.6 million in Q1 2024, $1.1 million for Q4 2023, and $1.2 million during Q2 2023.